The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has previously ...

Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime ...

More than a quarter of patients with early-stage cardiogenic shock had to be transferred to a higher level of care, progressed to a worse stage of shock, or died, according to a study in six US ...

WASHINGTON, DC—Early-stage cardiogenic shock leads to poor outcomes but is underrecognized, with only one in four affected patients having any indication in their electronic medical record (EMR) that ...

Treatment with a novel monoclonal antibody against circulating dipeptidyl peptidase 3 (cDPP3) led to complete reversal of cardiogenic shock in three compassionate use cases in Germany, according to a ...

Madrid, Spain – 31 August 2025: Compared with crushed ticagrelor, intravenous cangrelor provided immediate, effective platelet inhibition, with no increase in major bleeding and lower mortality rates ...